Anifrolumab in Systemic Lupus Erythematosus

To the Editor: Discordant results from the Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-1 trial(1) and the TULIP-2 trial (Jan. 16 issue)(2) have stimulated discussion about whether the British Isles Lupus Assessment Group-based Combined Lupus Assessment, the Systemic Lupus Erythematosus Responder Index, or some combination thereof accurately measures response in patients with active systemic lupus erythematosus (SLE).(3,4) Few practicing clinicians could name the components of either assessment, and in my experience, fewer still have ever used them. A simple, clinically meaningful question such as "Do you feel better?" could clarify this debate. Both trials evaluated multiple patient-reported outcome . . .